Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer

[1]  L. Emens.  Re-purposing cancer therapeutics for breast cancer immunotherapy , 2012, Cancer Immunology, Immunotherapy.

[2]  A. Luini,et al.  Invasive lobular breast cancer: subtypes and outcome , 2012, Breast Cancer Research and Treatment.

[3]  M. Orditura,et al.  Behavior of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Colon Cancer Patients Undergoing Surgery , 2011, Journal of Clinical Immunology.

[4]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[5]  I. Ellis,et al.  An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer , 2011, Breast Cancer Research and Treatment.

[6]  M. Watanabe,et al.  Regulatory T cells and breast cancer: implications for immunopathogenesis , 2010, Cancer and Metastasis Reviews.

[7]  Guobin Wang,et al.  Prognostic significance of regulatory T cells in tumor , 2010, International journal of cancer.

[8]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[9]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[10]  S. Perez,et al.  HER-2/neu as a target for cancer vaccines. , 2010, Immunotherapy.

[11]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[12]  S. V. Van Gool,et al.  Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination. , 2010, Journal of immunological methods.

[13]  Shimon Sakaguchi,et al.  Regulatory T cells exert checks and balances on self tolerance and autoimmunity , 2010, Nature Immunology.

[14]  C. Caux,et al.  Differences in tumor regulatory T-cell localization and activation status impact patient outcome. , 2009, Cancer research.

[15]  S. Briest,et al.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. , 2009, Cancer research.

[16]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Andreas Makris,et al.  Early breast cancer , 2009, The Lancet.

[18]  S. Ménard,et al.  FOXP3 expression and overall survival in breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Hailing Lu.  FOXP3 expression and prognosis: role of both the tumor and T cells. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Wallace,et al.  Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients , 2009, Cytometry. Part B, Clinical cytometry.

[22]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[23]  W. Isaacs,et al.  Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing , 2008, Clinical Cancer Research.

[24]  Lisa M. Ebert,et al.  The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. , 2008, Cancer research.

[25]  中村 力也.  Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer , 2008 .

[26]  M. Colombo,et al.  Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy , 2007, Nature Reviews Cancer.

[27]  Geraint T. Williams,et al.  CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer , 2006, PloS one.

[28]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[30]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[31]  D. Bloom.  CD4+CD25+FOXP3+ regulatory T cells in nonhuman primates , 2006 .

[32]  T. Giese,et al.  In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. , 2006, Blood.

[33]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[34]  Brian Barnett,et al.  Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals , 2004, Cancer Research.

[35]  J. Daling,et al.  Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. , 2003, Archives of internal medicine.

[36]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[38]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.